BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29775779)

  • 1. Metabolomics in breast cancer: A decade in review.
    McCartney A; Vignoli A; Biganzoli L; Love R; Tenori L; Luchinat C; Di Leo A
    Cancer Treat Rev; 2018 Jun; 67():88-96. PubMed ID: 29775779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
    Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
    Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer.
    Vignoli A; Risi E; McCartney A; Migliaccio I; Moretti E; Malorni L; Luchinat C; Biganzoli L; Tenori L
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods.
    Oakman C; Tenori L; Claudino WM; Cappadona S; Nepi S; Battaglia A; Bernini P; Zafarana E; Saccenti E; Fornier M; Morris PG; Biganzoli L; Luchinat C; Bertini I; Di Leo A
    Ann Oncol; 2011 Jun; 22(6):1295-1301. PubMed ID: 21199886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
    Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
    Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic studies of breast cancer in murine models: A review.
    Araújo R; Bispo D; Helguero LA; Gil AM
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165713. PubMed ID: 32014550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological and clinical significance of PARP1 protein expression in breast cancer.
    Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery.
    Patel S; Ahmed S
    J Pharm Biomed Anal; 2015 Mar; 107():63-74. PubMed ID: 25569286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
    Bonadona V; Dussart-Moser S; Voirin N; Sinilnikova OM; Mignotte H; Mathevet P; Brémond A; Treilleux I; Martin A; Romestaing P; Raudrant D; Rudigoz RC; Lenoir GM; Lasset C
    Breast Cancer Res Treat; 2007 Jan; 101(2):233-45. PubMed ID: 17061047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis.
    Huang S; Chong N; Lewis NE; Jia W; Xie G; Garmire LX
    Genome Med; 2016 Mar; 8(1):34. PubMed ID: 27036109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
    Hart CD; Vignoli A; Tenori L; Uy GL; Van To T; Adebamowo C; Hossain SM; Biganzoli L; Risi E; Love RR; Luchinat C; Di Leo A
    Clin Cancer Res; 2017 Mar; 23(6):1422-1431. PubMed ID: 28082280
    [No Abstract]   [Full Text] [Related]  

  • 17. A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response.
    Cardoso MR; Santos JC; Ribeiro ML; Talarico MCR; Viana LR; Derchain SFM
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29466297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
    Markopoulos C; van de Velde C; Zarca D; Ozmen V; Masetti R
    Eur J Surg Oncol; 2017 May; 43(5):909-920. PubMed ID: 27639633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and biological significance of microRNA-221 in breast cancer.
    Eissa S; Matboli M; Sharawy A; El-Sharkawi F
    Gene; 2015 Dec; 574(1):163-7. PubMed ID: 26253160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.